Fibromyalgia & Cannabis: Recent Research Highlights
What the newest peer‑reviewed literature says
All of the studies referenced below are indexed in PubMed, the U.S. National Library of Medicine’s database of peer‑reviewed research. The findings are summarized in plain language for education purposes only; they do not replace a conversation with a qualified physician.
Systematic review of medical‑cannabis formulations in fibromyalgia
A 2024 systematic review published in EULAR Rheumatology Open examined randomized controlled trials that used three cannabis‑derived products—nabilone, THC‑rich oil, and a mixed THC/CBD preparation called Bediol—in people with fibromyalgia. The authors reported modest improvements in pain scores and sleep quality compared with placebo, but the magnitude of benefit varied across the three formulations. Adverse events were generally mild, with dizziness and dry mouth noted most often. The review highlighted the small number of high‑quality trials and called for larger, longer‑term studies to clarify optimal dosing and safety.
Read the full abstract here.
Real‑world evidence of cannabinoid combinations for chronic pain
In a 2023 observational study appearing in Clinical Therapeutics, researchers collected real‑world data from 64 California residents diagnosed with fibromyalgia who were using various cannabis products. Participants reported reductions in overall pain intensity and improvements in daily functioning after using a blend of intoxicating (THC) and non‑intoxicating (CBD) cannabinoids. The study did not include a control group, so the authors cautioned that expectancy effects and other confounding factors could influence the results. Nonetheless, the authors suggested that mixed cannabinoid formulations merit further investigation in controlled trials.
Access the study summary here.
Low‑dose cannabidiol: pharmacokinetics and safety
The British Journal of Clinical Pharmacology published a 2023 review of low‑dose cannabidiol (≤2.5 mg/kg or ≤175 mg/day). While not limited to fibromyalgia, the review summarized how low oral doses of CBD are absorbed, metabolized, and generally well tolerated in healthy volunteers and patient groups. No serious safety signals emerged, and the most common side effects were mild gastrointestinal upset and fatigue. The authors emphasized that low‑dose CBD alone has not been proven to relieve fibromyalgia‑related pain, underscoring the need for disease‑specific trials.
Full details are available here.
Broader context: pain mechanisms and the gut‑brain axis
A 2024 article in Journal of Inflammation Research reviewed how the gut‑brain axis (GBA) influences chronic pain, including nociplastic conditions like fibromyalgia. The authors described how microbial metabolites, immune signaling, and neuroinflammation interact with central pain pathways. Although the paper did not test cannabis directly, it suggested that cannabinoids—by modulating inflammation and gut microbiota—could theoretically affect GBA signaling. The authors called for experimental studies that specifically explore this link.
Read the abstract These peer-reviewed studies are indexed on PubMed (U.S. National Library of Medicine); each links to its PubMed listing. Findings belong to the cited authors and journals.Sources & references
Ready to get your Florida medical marijuana card?
Disabled veteran-owned · on-site physician · no hidden fees.